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The authors report two cases of epidermal growth factor
receptor gene (EGFR)-mutant stage IV lung adenocarci-
nomas developing immunohistochemically proven squa-
mous cell carcinoma (SCC) “transformation” concurrently
with T790M EGFR mutation, leading to acquired resistance
to EGFR inhibitors. Moreover, the histologic change of
EGFR-mutant lung adenocarcinoma into SCC has been
recently reported in literature. The histological trans-
formation to SCC appears as a novel mechanism of acquired
EGFR TKI resistance in EGFR-mutated adenocarcinomas
and it may be challenging for treatment.
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A 74-year-oldwomen, a former smoker, presentedwith
persistent cough. Chest radiography, whole-body com-
puted tomography (CT), and positron emission tomogra-
phy revealed two nodules in the left lung, enlarged
mediastinal lymph nodes, and a mass of the left adrenal
gland. The findings of brain imaging were negative. Bron-
chial biopsy showed a lung adenocarcinoma (thyroid
transcription factor 1 [TTF-1] positive, p40 negative). The
mutational analysis by matrix-assisted laser desorption/
ionization time-of-flight revealed an exon 21 epidermalgrowth factor receptor gene (EGFR) L858R mutation,
excluding additional alterations (LungCarta Panel v1.0,
Agena Bioscience, San Diego, CA). Sanger sequencing
confirmed the molecular data. In January 2014, the patient
began taking gefitinib. Her symptoms improved rapidly,
and a CT scan (inMay 2014) revealed a partial response. In
October2014, thepatient complainedofdry coughandaCT
scan showed enlargement of her lung lesions. A bronchial
rebiopsy surprisingly provided evidence of a squamous cell
carcinoma (SCC) (p40 positive, TTF-1 negative). In molec-
ular investigations, tumor cells harbored the original exon
21 EGFR mutation and also carried an exon 20 T790M
mutation. Second-line chemotherapy (carboplatin and
vinorelbine) achieved stabilization of the disease, and
radiosurgery successfully controlled the occurrence of
brain metastasis. As of September 2015, the patient is still
alive with stable disease.
Case 2
A 79-year-old woman, a never-smoker, was admitted
to the hospital for thoracic trauma and hemoptysis. Chest
CT and positron emission tomography scans revealed aJournal of Thoracic Oncology Vol. 11 No. 4: e49-e51
Table 1. Summary of the Main ClinicoPathologic and Molecular Characteristics of Change/Transformation of EGFR-Mutated


















F/66 Never IV ex19 Erlotinib (8) None None DOD (9) 2
F/79 Never IV delE746-A750 Gefitinib (15) T790M RT
Gefitinib
AWD (24) Current article
F/74 Former IV L858R Gefitinib (10) T790M RT AWD (20) Current article
aMonths to progression to EGFR TKI.
EGFR, epidermal growth factor receptor gene; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; F, female; mo, months; RT, radiotherapy;
cis, cisplatin; carbo, carboplatin; pem, pemetrexed; gem, gemcitabine; DOD, died of disease; AWD, alive with disease.
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prepared from pleural effusion and bronchial biopsies
showed a lung adenocarcinoma (TTF-1 positive, p40
negative). Molecular analysis revealed an exon 19
delE746-A750 EGFR mutation. Gefitinib was started in
July 2013 and resulted in partial remission of the lung
and pleural lesions. In October 2014, a right brain
metastasis was treated with stereotactic radiotherapy.
In February 2015, pleural effusion and brain metastasis
reappeared. A bronchial rebiopsy revealed a SCC (p40
positive, TTF-1 negative) harboring naive delE746-A750
and exon 20 T790M missense mutations. Gefitinib wasFigure 1. Computed tomography scans showing the clinical cou
and case 2 (bottom). Histologic change from adenocarcinoma (h
immunoreactivity [left]) to squamous cell carcinoma (hematoxcontinued; the thoracic disease remained stable for 7
months, but soft-tissue metastases from SCC occurred at
the left leg.
Discussion
The histologic change of EGFR-mutant lung adenocar-
cinoma into SCC has been recently reported in two never-
smokingwomenwhounderwent rebiopsywhen resistance
to erlotinib occurred.1,2 Here we report two additional
cases of EGFR-mutant stage IV adenocarcinomas devel-
oping concurrently with immunohistochemically proven
SCC “transformation” and T790M EGFR mutation leadingrse during administration of gefitinib therapy in case 1 (top)
ematoxylin and eosin stain with thyroid transcription factor 1
ylin and eosin stain with p40 immunoreactivity [right]).
April 2016 SCC Transformation and T790M e51to acquired resistance to gefitinib after 15 and 10 months
(Table 1). SCC harbored the original EGFR mutation
together with T790M (Fig. 1). In EGFR-mutated adeno-
carcinoma, so-called transformation could be secondary to
metaplastic plasticity of tumor cells,3 but the possibility of
unsampled combined (i.e., adenosquamous)4 neoplasms
selecting a different tumor component under the pressure
of an EGFR tyrosine kinase inhibitor (TKI) cannot be
excluded. In their case, Kuiper et al.1 reported an additional
mutation concomitant to the naive L858R, namely,
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha gene (PIK3CA) exon 20 (H1047R).
Transformation to SCC appears as a novel mech-
anism of acquired EGFR TKI resistance in EGFR-
mutated adenocarcinomas. The therapeutic strategies
to adopt in these cases may be challenging and
are still unclear because subsequent management
could be based on the new histologic findings (SCC-
based chemotherapy) rather than on novel molecularcharacteristics (third-generation pyrimidine-based
EGFR TKIs).
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